191 related articles for article (PubMed ID: 26366398)
1. MET deregulation in breast cancer.
Minuti G; Landi L
Ann Transl Med; 2015 Aug; 3(13):181. PubMed ID: 26366398
[TBL] [Abstract][Full Text] [Related]
2. Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
Miranda O; Farooqui M; Siegfried JM
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30134579
[TBL] [Abstract][Full Text] [Related]
3. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
4. HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis.
Gaudino G; Yang H; Carbone M
Biomedicines; 2014 Nov; 2(4):327-344. PubMed ID: 28548074
[TBL] [Abstract][Full Text] [Related]
5. Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer.
Sylvester PW
Clin Transl Med; 2014 Dec; 3(1):30. PubMed ID: 26932375
[TBL] [Abstract][Full Text] [Related]
6. TGFβ1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer.
Breunig C; Erdem N; Bott A; Greiwe JF; Reinz E; Bernhardt S; Giacomelli C; Wachter A; Kanthelhardt EJ; Beißbarth T; Vetter M; Wiemann S
Mol Oncol; 2018 Sep; 12(9):1447-1463. PubMed ID: 30004628
[TBL] [Abstract][Full Text] [Related]
7. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
Yap TA; Sandhu SK; Alam SM; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
[TBL] [Abstract][Full Text] [Related]
8. Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c-Met-Mediated Epithelial-to-Mesenchymal Transition.
Hsieh YS; Liao CH; Chen WS; Pai JT; Weng MS
J Cell Biochem; 2017 Dec; 118(12):4639-4651. PubMed ID: 28485480
[TBL] [Abstract][Full Text] [Related]
9. The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer.
Elliott BE; Hung WL; Boag AH; Tuck AB
Can J Physiol Pharmacol; 2002 Feb; 80(2):91-102. PubMed ID: 11934261
[TBL] [Abstract][Full Text] [Related]
10. The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer.
Parizadeh SM; Jafarzadeh-Esfehani R; Fazilat-Panah D; Hassanian SM; Shahidsales S; Khazaei M; Parizadeh SMR; Ghayour-Mobarhan M; Ferns GA; Avan A
IUBMB Life; 2019 Jul; 71(7):802-811. PubMed ID: 31116909
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.
Owusu BY; Galemmo R; Janetka J; Klampfer L
Cancers (Basel); 2017 Apr; 9(4):. PubMed ID: 28420162
[TBL] [Abstract][Full Text] [Related]
12. MET targeted therapy for lung cancer: clinical development and future directions.
Feng Y; Ma PC
Lung Cancer (Auckl); 2012; 3():53-67. PubMed ID: 28210125
[TBL] [Abstract][Full Text] [Related]
13. MET signaling: novel targeted inhibition and its clinical development in lung cancer.
Feng Y; Thiagarajan PS; Ma PC
J Thorac Oncol; 2012 Feb; 7(2):459-67. PubMed ID: 22237263
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.
Owusu BY; Bansal N; Venukadasula PK; Ross LJ; Messick TE; Goel S; Galemmo RA; Klampfer L
Oncotarget; 2016 May; 7(20):29492-506. PubMed ID: 27121052
[TBL] [Abstract][Full Text] [Related]
15. 13
Souid S; Elsayed HE; Ebrahim HY; Mohyeldin MM; Siddique AB; Karoui H; El Sayed KA; Essafi-Benkhadir K
Mol Carcinog; 2018 Nov; 57(11):1507-1524. PubMed ID: 29978911
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte growth factor-induced mesenchymal-epithelial transition factor activation leads to insulin-like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells.
Liu R; Tang W; Han X; Geng R; Wang C; Zhang Z
Oncol Lett; 2018 Nov; 16(5):5983-5991. PubMed ID: 30333869
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
18. Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.
Landi L; Minuti G; D'Incecco A; Cappuzzo F
Curr Opin Oncol; 2013 Mar; 25(2):130-6. PubMed ID: 23385860
[TBL] [Abstract][Full Text] [Related]
19. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review).
Moriyama T; Kataoka H; Koono M; Wakisaka S
Int J Mol Med; 1999 May; 3(5):531-6. PubMed ID: 10202187
[TBL] [Abstract][Full Text] [Related]
20. Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells.
Hung CM; Kuo DH; Chou CH; Su YC; Ho CT; Way TD
J Agric Food Chem; 2011 Sep; 59(17):9683-90. PubMed ID: 21806057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]